
About QBiotics
QBiotics is a Healthcare company based in Brisbane (Australia) founded in 2000 by Victoria Gordon and Paul Reddell. Small molecules from plant extracts are developed for medical applications. It operates on a HealthTech model. QBiotics has raised $98.07 million across 3 funding rounds from investors including TDM Growth Partners. Its chief executive, as recorded, is Victoria Gordon. QBiotics offers products and services including Tigilanol Tiglate, EBC-1013, and STELFONTA. Its focus areas include Biotechnology, Oncology and Wound Healing. Its legal entity is QBiotics Group.
Company details
QBiotics is engaged in the discovery and development of novel cell signaling small molecules for challenging medical conditions. The company operates in the healthcare sector, specializing in oncology and wound healing solutions. Its lead oncology drug, Tigilanol Tiglate, is in clinical Phase II trials for soft tissue sarcomas and head and neck cancers. Additionally, EBC-1013 is being developed for chronic and acute wounds, with a Phase I trial planned. Veterinary oncology product STELFONTA is commercialized for mast cell tumors in dogs. Innovation is driven by proprietary platforms like EcoLogic and phenotypic screening, leveraging Australias tropical rainforest molecular diversity.
- Headquarters Brisbane, Australia
- Founders Victoria Gordon, Paul Reddell
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website qbiotics.com
- Social LinkedIn
- Legal Name Qbiotics Group
- Total Equity Funding$98.07M (USD)
in 3 rounds
- Latest Funding Round$64.42M (USD), Series C
Jun 2021
- Investors
Products & Services of QBiotics
QBiotics offers a comprehensive portfolio of products and services, including Tigilanol Tiglate, EBC-1013, and STELFONTA.
Developed as treatment for soft tissue sarcomas oncology.
Designed for treatment of chronic and acute wounds.
Approved for non-resectable mast cell tumors in dogs.
Funding Insights of QBiotics
QBiotics has successfully raised a total of $98.07M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $64.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $98.07M
- Total Rounds 3
- Last Round Series C — $64.42M
- First Round $22.1M
(Jun 2016)
- Investors Count 1
All 3 funding rounds of QBiotics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $64.42M | Series C | – | TDM Growth Partners | – |
| Feb 2020 | $11.55M | Series B | – | – | – |
| Jun 2016 | $22.1M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in QBiotics
QBiotics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TDM Growth Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth capital is offered by TDM Growth Partners. | tdmgrowthpartners.com | Sydney, Australia |
Investor details for QBiotics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of QBiotics
3 people are tracked at QBiotics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Victoria Gordon | Co-Founder & CEO & MD | Leadership |
Paul Reddell | Co-Founder | Leadership |
Stephen Doyle | CEO & MD | Leadership |
Complete people profiles for QBiotics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of QBiotics
3 dated milestones of QBiotics across 21 years, from founding to its latest funding, stage changes and deals.
- Founded QBiotics is founded.
- Funding First funding round of $22.1M.
- Funding Latest funding round, Series C, of $64.4M.
Web traffic of QBiotics
The website of QBiotics (qbiotics.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▼ 56.3% vs previous month
Websites whose visitors overlap most with QBiotics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| petermac.org | 100% | 102.2K | #354,410 | View details | |
| vacancer.com | 64% | #2,297,628 | View details | ||
floridahospitalcancer.com | floridahospitalcancer.com | 62% | – | ||
| immunocore.com | 58% | 11.9K | #2,192,904 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qbiotics
Complete news archive for QBiotics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QBiotics
QBiotics was founded in 2000 and raised its 1st funding round 16 years after it was founded.
QBiotics is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.
Victoria Gordon is the CEO of QBiotics, as recorded in our data. They have also founded this company.
QBiotics is a funded company, having raised a total of $98.07M across 3 funding rounds to date. The company's 1st funding round was a Series B of $22.1M, raised on Jun 2016.
QBiotics is engaged in the discovery and development of novel cell signaling small molecules for challenging medical conditions. The company operates in the healthcare sector, specializing in oncology and wound healing solutions. Its lead oncology drug, Tigilanol Tiglate, is in clinical Phase II trials for soft tissue sarcomas and head and neck cancers. Additionally, EBC-1013 is being developed for chronic and acute wounds, with a Phase I trial planned. Veterinary oncology product STELFONTA is commercialized for mast cell tumors in dogs. Innovation is driven by proprietary platforms like EcoLogic and phenotypic screening, leveraging Australias tropical rainforest molecular diversity.
QBiotics offers Tigilanol Tiglate, EBC-1013, and STELFONTA.
QBiotics has 1 investor. Key investors include TDM Growth Partners.
QBiotics operates through Qbiotics Group.
